BLTE — BELITE BIO, INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1889109 ·
Last close
$157.72
Market Cap
$6.35B
52W High
$200.00
52W Low
$105.88
ADV30
175,242
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -36,910,000 -30,273,000 789,738,000 — 18,678,000
Jun 2026 0 — -34,907,000 -28,412,000 791,582,000 — 14,946,000
Mar 2026 0 — -32,684,000 -26,938,000 811,271,000 — 15,483,000
Dec 2025 0 — -28,077,000 -25,324,000 780,556,000 352,932,000 10,070,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,385,000
Investing CF
$-303,734,000
Financing CF
$510,118,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-185,258,000
Inventory
—
Receivables
$718,000
ST Investments
$139,490,000
EBIT TTM
$-112,087,000
Pretax Income TTM
$-102,309,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -84,208,000 -77,611,000 780,556,000 10,070,000 770,486,000 -36,988,000
Dec 2024 0 -39,996,000 -36,144,000 152,132,000 6,311,000 145,821,000 -29,234,000
Dec 2023 0 -31,668,000 -31,632,000 94,642,000 4,211,000 90,431,000 -29,837,000
Dec 2022 0 -12,821,000 -12,648,000 44,273,000 2,772,000 41,501,000 -11,458,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.26

Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $105.00 · spot: $156.23 · call volume: 36 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
ORKA Oruka Therapeutics, Inc. $6.53B $96.32 —
ARWR ARROWHEAD PHARMACEUTICALS, INC. $6.08B $42.99 —
MIRM Mirum Pharmaceuticals, Inc. $6.00B $91.95 —
LGND LIGAND PHARMACEUTICALS INC $5.86B $293.81 —
AXSM Axsome Therapeutics, Inc. $7.15B $135.95 —

News headlines (Yahoo Finance, 1h cache)

Belite Bio (BLTE) Q3 2026 Earnings Call Transcript
2026-11-13 07:02 · Yahoo
What Belite Bio (BLTE) Said on Its Q3 Earnings Call
2026-11-13 02:14 · Yahoo
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-12 11:00 · Yahoo
Belite Bio (BLTE) Stock May Trade Above Fair Value On Book Value
2026-11-10 06:11 · Yahoo
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
2026-11-05 13:00 · Yahoo
Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
2026-10-17 10:13 · Yahoo
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
2026-10-14 20:00 · Yahoo
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
2026-10-01 12:00 · Yahoo
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
2026-09-09 13:55 · Yahoo
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
2026-09-03 04:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.